Tumor-infiltrating lymphocytes for the treatment of metastatic cancer
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. / Geukes Foppen, M H; Donia, M; Svane, I M; Haanen, J B A G.
I: Molecular Oncology, Bind 9, Nr. 10, 12.2015, s. 1918-35.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Tumor-infiltrating lymphocytes for the treatment of metastatic cancer
AU - Geukes Foppen, M H
AU - Donia, M
AU - Svane, I M
AU - Haanen, J B A G
N1 - Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
PY - 2015/12
Y1 - 2015/12
N2 - Over the past few years melanoma incidence has been rising steadily, resulting in an increase in melanoma related mortality. Until recently, therapeutic options for metastatic melanoma were scarce. Chemotherapy and, in some countries, IL-2 were the only registered treatment modalities. In the last five years, treatment with immunotherapy (anti CTLA-4, anti PD-1, or the combination of these antibodies) has shown very promising results and was able to improve survival in patients with metastatic melanoma. Adoptive cell therapy using tumor-infiltrating lymphocytes is yet another, but highly promising, immunotherapeutic strategy for patients with metastatic melanoma. This review will discuss the development of TIL as a treatment option for melanoma, its mode of action and simplification over time, and the possibilities to expand this therapy to other types of cancer. Also, the future directions of TIL based therapies will be highlighted.
AB - Over the past few years melanoma incidence has been rising steadily, resulting in an increase in melanoma related mortality. Until recently, therapeutic options for metastatic melanoma were scarce. Chemotherapy and, in some countries, IL-2 were the only registered treatment modalities. In the last five years, treatment with immunotherapy (anti CTLA-4, anti PD-1, or the combination of these antibodies) has shown very promising results and was able to improve survival in patients with metastatic melanoma. Adoptive cell therapy using tumor-infiltrating lymphocytes is yet another, but highly promising, immunotherapeutic strategy for patients with metastatic melanoma. This review will discuss the development of TIL as a treatment option for melanoma, its mode of action and simplification over time, and the possibilities to expand this therapy to other types of cancer. Also, the future directions of TIL based therapies will be highlighted.
U2 - 10.1016/j.molonc.2015.10.018
DO - 10.1016/j.molonc.2015.10.018
M3 - Review
C2 - 26578452
VL - 9
SP - 1918
EP - 1935
JO - Molecular Oncology
JF - Molecular Oncology
SN - 1574-7891
IS - 10
ER -
ID: 162854492